Evaluation of humoral response to tumor antigens using recombinant expression-based serological mini-arrays (SMARTA)

Lagarkova, Maria A.; Koroleva, Ekaterina P.; Kuprash, Dmitry V.; Boitchenko, Veronica E.; Kashkarova, Ulyana A.; Nedospasov, Sergei A.; Shebzukhov, Yuriy V.

doi:10.1016/s0165-2478(02)00209-2

Cited by 29 publications

(21 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15,16 None of the 194 colon cancer sera used in our study was positive for NY-CO-9 using recombinant phage assay in SMARTA format. 14 Not only HDAC3, but all 3 best-studied Class I HDAC are overexpressed frequently in tumors of patients with colorectal cancer, in agreement with the earlier reports on the HDAC1 overexpression in gastric and prostate cancers. 11,12 In colon cancer we found that the protein levels of HDAC1, HDAC2 and HDAC3, but not their mRNA levels, were increased in tumors as compared to non-cancerous colon mucosa from the same patients.…”

Section: Discussionsupporting

confidence: 88%

“…14 Briefly, 0.5 ml drops of phage stocks ( 500 pfu/ml) were spotted directly to the LB agar plates containing a layer of solidified LB/0.8% agarose/5 mM IPTG premixed with E. coli XL-1 Blue MRF' cells. Plaque lysates were transferred to the nitrocellulose membranes and resulting arrays were incubated with allogeneic sera and developed as described above.…”

Section: Serological Mini-arrays Of Recombinant Tumor Antigensmentioning

confidence: 99%

“…14,[17][18][19][20] In particular, one of the positive clones from an ovarian cancer-derived cDNA library, screened with autologous serum, MO-OVA-91, was identified by sequence analysis as a partial transcript of human HDAC3 gene lacking 448 bp of the complete cDNA at the 5 0 -region. The deduced amino acid sequence of MO-OVA-91 corresponded to HDAC3 amino acid residues 132-428.…”

Section: Initial Identification Of Serex Clone Mo-ova-91 As a Fragmenmentioning

confidence: 99%

“…pBK-CMV-based recombinant phagemids were excised in vivo and used for transfecting XLOLR E. coli cells. The results of subsequent serological analysis of the clones encoding 3 Class I HDAC using SMARTA technique 14 and by Western blotting are shown in Figure 1a,b, respectively. Analysis of sera from 10 MO-OVA-91 (HDAC3)-positive patients demonstrated that they recognized only HDAC3, not the other tested HDAC (Table I).…”

Section: Hdac3 Is a Serologically Defined Colon Cancer Antigenmentioning

confidence: 99%

“…Antibodies against HDAC3 were never observed in normal donors using SMARTA format of screening. 14 We mapped corresponding B cell epitopes to a non-conserved C-terminal region of HDAC3 protein and carried out expression analysis to address the putative link between seroconversion and HDAC overexpression in tumors. In conclusion, HDAC3 seems to be a novel serologically defined biomarker that can be potentially used for diagnosis and for disease monitoring in colon cancer.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Antibody response to a non‐conserved C‐terminal part of human histone deacetylase 3 in colon cancer patients

Shebzukhov

Koroleva

Khlgatian

et al. 2005

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Antibodies to cancer antigens can often be detected in the sera of patients, although the mechanism of the underlying humoral immune response is poorly understood. Using immunoscreening of tumor-derived cDNA expression libraries (SEREX), we identified human histone deacetylase 3 (HDAC3) as serologically defined antigen in colon cancer. Closely related HDAC1 and HDAC2 do not elicit humoral response in colon cancer patients. We show that the C-terminal region of HDAC3 protein lacking the homology to other Class I HDAC contains at least 3 distinct B-cell epitopes that are recognized by the serum antibodies. HDAC3 in combination with other SEREX antigens may become a useful molecular biomarker with diagnostic or prognostic value for a subset of colon cancer patients. (Supplementary material for this article can be found on the International Journal of Cancer website at

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Serological Mini-arrays Of Recombinant Tumor Antigensmentioning

confidence: 99%

Section: Initial Identification Of Serex Clone Mo-ova-91 As a Fragmenmentioning

confidence: 99%

Section: Hdac3 Is a Serologically Defined Colon Cancer Antigenmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Antibody response to a non‐conserved C‐terminal part of human histone deacetylase 3 in colon cancer patients

Shebzukhov

Koroleva

Khlgatian

et al. 2005

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Children's eating attitudes test: Validation in a sample of Spanish schoolchildren

Rojo-Moreno

García-Miralles

Plumed

et al. 2010

Intl J Eating Disorders

View full text Add to dashboard Cite

show abstract

Serologic detection of diffuse large B‐cell lymphoma‐associated antigens

Liggins

Guinn

Hatton

et al. 2004

Intl Journal of Cancer

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) accounts for 30 -40% of all adult non-Hodgkin's lymphomas, yet the understanding of its underlying genetic abnormalities remains poor. Our present study used the serological analysis of recombinant cDNA expression libraries (SEREX) technique to identify DLBCL-associated antigens. SEREX screening of testis libraries has previously identified cancer-testis antigens (CTAs) that may act as disease-specific targets for immunotherapy. Screening a testis cDNA expression library with serum from a DLBCL patient identified a total of 94 positive clones, representing 28 distinct antigens. Two of these antigens were novel, 8 were previously uncharacterised, and the remainder were proteins of known function. Screening of the antigens with sera from DLBCL (n ‫؍‬ 10), acute myeloid leukaemia (AML, n ‫؍‬ 10) and chronic myeloid leukaemia (CML, n ‫؍‬ 10) patients, alongside normal healthy donor controls (n ‫؍‬ 20), revealed that 7 of the antigens were recognised by DLBCL sera but not normal donor sera, whilst 2 of these antigens were also recognised by leukaemic sera. Some of the genes identified here were already known to be transcribed in DLBCL. The mRNA expression of the majority of the remaining antigens was confirmed in DLBCL cell lines using reverse-transcriptase PCR (RT-PCR). Our study identified a number of DLBCL associated antigens that may be suitable as prognostic/diagnostic markers and/or for the immunotherapy of haematologic malignancies.

show abstract

Evaluation of humoral response to tumor antigens using recombinant expression-based serological mini-arrays (SMARTA)

Cited by 29 publications

References 10 publications

Antibody response to a non‐conserved C‐terminal part of human histone deacetylase 3 in colon cancer patients

Antibody response to a non‐conserved C‐terminal part of human histone deacetylase 3 in colon cancer patients

Children's eating attitudes test: Validation in a sample of Spanish schoolchildren

Serologic detection of diffuse large B‐cell lymphoma‐associated antigens

Contact Info

Product

Resources

About